Literature DB >> 26521996

Is there any correlation between levels of serum ostepontin, CEA, and FDG uptake in lung cancer patients with bone metastasis?

A K Ayan1, B Erdemci2, E Orsal3, Z Bayraktutan4, E Akpinar5, A Topcu6, M Turkeli7, B Seven8.   

Abstract

OBJECTIVE: In this study, an evaluation was made of the relationship between the serum levels of carcinoembryonic antigen (CEA), osteopontin (OPN), and the semi-quantitative parameters of 18-fluoro-2-deoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) in lung cancer patients with bone metastasis.
MATERIAL AND METHODS: The evaluation included 42 non-small cell lung cancer (NSCLC) and 31 small cell lung cancer (SCLC) patients who were referred to our institution for staging by (18)F-FDG PET/CT. The biochemical parameters measured included CEA and OPN serum levels.
RESULTS: Serum levels of OPN in NSCLC patients with and without bone metastasis were 21.20±4.97 ng/ml and 13.33±4.53 ng/ml, respectively (p<0.05). In SCLC patients with and without bone metastasis serum OPN levels were 23.95±4.78 ng/ml and 17.30±3.09 ng/ml, respectively (p<0.05). Serum levels of CEA in NSCLC patients with and without bone metastasis were 33.79±6.49 ng/ml and 11.74±2.96 ng/ml, respectively (p<0.05). In SCLC patients with and without bone metastasis serum levels of CEA were 28.93±4.59 ng/ml and 13.88±4.47 ng/ml, respectively (p<0.05). There were no correlations between primary tumor SUVmax, and serum levels of CEA and OPN.
CONCLUSIONS: Bone metastasis can be detected in patients with lung cancer by measuring CEA and OPN levels. Increased levels of CEA and OPN levels may be considered an early warning sign in patients needing accurate imaging, as they are at higher risk of bone metastasis.
Copyright © 2015 Elsevier España, S.L.U. and SEMNIM. All rights reserved.

Entities:  

Keywords:  Bone metastasis; CEA; Cáncer de pulmón; Lung cancer; Metástasis ósea; OPN; Positron emission tomography; Tomografía de emisión de positrones

Mesh:

Substances:

Year:  2015        PMID: 26521996     DOI: 10.1016/j.remn.2015.09.002

Source DB:  PubMed          Journal:  Rev Esp Med Nucl Imagen Mol        ISSN: 2253-654X            Impact factor:   1.359


  5 in total

1.  Risk factor analysis of bone metastasis in patients with non-small cell lung cancer.

Authors:  Yang Li; Chongqing Xu; Qiquan Yu
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

2.  Serum CEA and CYFRA Levels in ALK-rearranged NSCLC Patients: Correlation With Distant Metastasis.

Authors:  Takeshi Numata; Takeo Endo; Hidetoshi Yanai; Kyoko Ota; Yusuke Yamamoto; Kei Shimizu; Hideyasu Yamada; Kenji Hayashihara; Shinichiro Okauchi; Hiroaki Satoh; Yutaka Yamada; Tomohiro Tamura; Kazuto Saito; Norihiro Kikuchi; Koichi Kurishima; Hiroichi Ishikawa; Hiroko Watanabe; Toshihiro Shiozawa; Nobuyuki Hizawa; Yasunori Funayama; Shigen Hayashi; Hiroyuki Nakamura; Takaaki Yamashita
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

3.  [Risk Factors of Non-small Cell Lung Cancer with Bone Metastasis after Therapy].

Authors:  Yuanshan Yao; Yinjie Zhou; Zhenhua Yang; Haibo Shen
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2018-06-20

4.  Development and Validation of a Novel Nomogram for Predicting Tumor-Distant-Metastasis in Patients with Early T1-2 Stage Lung Adenocarcinoma.

Authors:  WeiGuo Gu; MingBin Hu; WeiJia Wang; Chao Shi; JinHong Mei
Journal:  Ther Clin Risk Manag       Date:  2020-12-10       Impact factor: 2.423

5.  Clinical risk factors of carbohydrate antigen-125, cytokeratin fragment 19, and neuron-specific enolase in liver metastases from elderly lung cancer patients.

Authors:  Tao Cheng; Jun Chen; Ping Ying; Hong Wei; Huiye Shu; Min Kang; Jie Zou; Qian Ling; Xulin Liao; Yixin Wang; Yi Shao
Journal:  Front Genet       Date:  2022-09-29       Impact factor: 4.772

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.